Matthew E. Langer, Partner

Dr. Matthew E. Langer is an internationally recognized patent-law expert in life sciences. He has extensive experience with representing start-up, mid-size and large privately and publicly held life sciences companies on patent- related matters and with respect to intellectual property aspects of investments, joint ventures, acquisitions, license and partnership negotiations and public offerings of securities. Additionally, Dr. Langer represents clients in the areas of diligence, patent prosecution, patentability analysis, claim construction and validity, infringement analysis, freedom to operate, patent term extension, data exclusivity, patent exhaustion, appellate review, standing and damages.

Dr. Langer has experience in a wide array of technologies including pharmaceuticals, biotechnology, medical devices, green technology, organic synthesis, inorganic chemistry, orthodontics, cosmetics, oncology, inflammation, ocular diseases, cardiovascular disease, dyslipidemia, Alzheimer's disease, depression, sexual dysfunction, orphan diseases, isotopically labeled drugs, antibodies, peptides, polymers, opioids, antidepressants, anti-platelet agents, drug delivery formulations, drug purification, aptamers, liposomes, pigments, catalysts, surfactants, sunscreens and ethnobotanicals.

'Someone with business expertise to go along with patent prosecution skills'

LMG Life Sciences 2014

Representative matters include:

  • Advised Cerenis Therapeutics on intellectual-property matters in connection with its IPO
  • Advised Ophthotech Corp. on intellectual-property matters in connection with its IPO
  • Advised Ophthotech Corp. on intellectual-property matters in connection with a $175 million financing round
  • Represented Genentech in connection with its acquisition by Roche
  • Successfully defended Estee Lauder patent and granted request to reexamine competitor patent in reexamination proceedings
  • Represented Gemin X Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing first-in-class cancer therapeutics, in its acquisition by Cephalon, Inc. for $225 million upfront cash payment, and potential earn out payments of up to $300 million 
  • Represented Biocompatibles in connection with its acquisition of Brachy Sciences and its affiliates World Wide Medical Technologies, LLC and Advanced Care Medical, Inc.

Seen as a leading expert in his field, Dr. Langer was selected in 2012-2015 as a "Life Science Star" by LMG Life Sciences. He also has been honored as an "IP Star" by Managing Intellectual Property, as a New York "Super Lawyer" by Super Lawyers and as a patent law expert by Euromoney.

Prior to joining the Firm, Dr. Langer was a partner at Wilson Sonsini; he also practiced law at WilmerHale and Pennie & Edmonds LLP. Before starting his legal career, he served as a research scientist with Unilever Research in Edgewater, New Jersey. In this position, he synthesized, characterized and evaluated sunscreens, artificial tanning agents, fluorescent whitening agents and oxidizing agents for skin and fabric care. Previously, he was a staff chemist at GE Corporate Research and Development. Dr. Langer is a joint inventor named on numerous United States patents assigned to Lever Brothers Company or GE.

Dr. Langer received his JD from Fordham University School of Law and has a PhD degree in Organic Chemistry from Yale University. He also received his BS degree in Chemistry from Tufts University.

Dr. Langer is admitted to practice in New York and before the U.S. Patent and Trademark Office.


  • Fordham University School of Law
    JD, 1998
  • Yale University
    PhD Chemistry, 1987
  • Tufts University
    BS, 1981

Court Admissions

  • Court of Appeals, Federal Circuit
  • Supreme Court of the United States

Bar Admissions

  • New York
  • Registered to practice before the United States Patent & Trademark Office (USPTO)

Select Publications and Speaking Engagements


  • Co-author, "Synthesis of Polyesters from Dimethyl Terephthalate, Ethylene Glycol, Poly(Ethylene Glycol) and 4,4-Bis(carbomethoxy)stilbene, and Characterization by ¹H and 2-D N.M.R." 33(22) Polymer 4862-65, 1992 
  • Co-author with P. Liberati, "Synthesis and Characterization of Poly(Vinyl 4-Methoxycinnamate)," 32(15) Polymer Communications 453-55, 1991 
  • Co-author with S. Danishefsky, "On the Use of the Imine-Diene Cyclocondensation Reaction in the Synthesis of Yohimbine Congeners," 26(48) Tetrahedron Letters 5983-86, 1985 
  • Co-author with S. Danishefsky, "On the Steric Course of the Reduction of 2-Alkoxy-4-Pyranones: A Remarkable Demonstration of Anomeric Control," 50 Journal of Organic Chemistry 3672-74, 1985

Speaking Engagements:

  • "U.S. Patent Practice Update," The Institute of Patent and Trade Mark Attorneys of Australia, 2016 Annual Conference, Gold Coast, Queensland, Australia, April 14, 2016
  • "Overcoming Obviousness Rejections in the United States," The Institute of Patent and Trade Mark Attorneys of Australia, 2016 Annual Conference, Gold Coast, Queensland, Australia,
    April 15, 2016
  • "Patent Law Basics," Weill Cornell Medical College of Cornell University, August 21, 2013
  • "Developing a Patent Strategy: An Overview," W.P. Carey Program in Entrepreneurship and Management, Johns Hopkins University, Baltimore, Maryland, September 20, 2010, and September 23, 2009 
  • "IP: What Matters to Investors," Yale University Start-Up Boot Camp 2009, Yale University, New Haven, Connecticut, November 3, 2009 
  • "Starting a Life-Sciences Company: What Researcher Entrepreneurs Need to Know," Memorial Sloan-Kettering Cancer Center, New York, October 21, 2009 
  • "Start-Ups: Venture Capital and Why Intellectual Property Matters," Making Medicine Series, Harvard Medical School, Boston, Massachusetts, September 30, 2009 
  • "University Inventors: Should You Start Your Own Company?" Invention 2 Innovation, Georgetown University, Washington, D.C., September 24, 2009 
  • "IP and the Life Science Startup," Technology & Life Science Entrepreneurs Boot Camp 2009, Johns Hopkins School of Medicine, Baltimore, Maryland, February 12, 2009 
  • "Effectively Maintaining Patent Protection and Enforcement in Light of Upcoming Regulations," PharmaBiotech IP Summit, Philadelphia, May 28, 2008 
  • "Legal Consequences of KSR Int'l Co. v Teleflex Inc.," BIO Intellectual Property Counsels' Committee Meeting, Santa Monica, California, April 1, 2008
New York
The Grace Building
1114 Avenue of the Americas
New York, New York 10036-7798

Phone: +1 212 479 6280
Fax: +1 212 479 6275
Download vcard (Download vcard)
Download PDF (Download PDF)

Related Media

Related Practices

©2003-2016 Cooley LLP and Cooley (UK) LLP. All rights reserved.
COOLEY® and the COOLEY LLP® logo are registered U.S. service marks of Cooley LLP.
Cooley was founded in 1920 – for our story, visit our timeline.